0MTD Stock Chart & Stats
kr460.74
kr4.54(1.00%)
At close: 4:00 PM EDT
kr460.74
kr4.54(1.00%)
Day’s Range― - ―
52-Week Rangekr310.80 - kr486.40
Previous CloseN/A
Volume63.10K
Average Volume (3M)101.17K
Market Cap
kr156.74B
Enterprise Valuekr178.24B
Total Cash (Recent Filing)kr1.08B
Total Debt (Recent Filing)kr17.59B
Price to Earnings (P/E)114.4
Beta1.06
Next Earnings
Oct 27, 2026EPS Estimate
6.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.97
Shares Outstanding357,636,500
10 Day Avg. Volume81,243
30 Day Avg. Volume101,165
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr572.50Price Target Upside24.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)19.09
Revenue Forecast (FY)kr33.29B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSteady revenue expansion indicates continued demand for Sobi’s rare-disease portfolio and supports a durable commercial foundation. Growth on top of prior annual gains can broaden the earnings base, strengthen reinvestment capacity, and provide operating leverage as the business scales.
Cash GenerationStrong and growing free cash flow gives Sobi internal funding for research, commercialization, partnerships, and other strategic priorities. Cash generation that remains high relative to reported net income also supports earnings quality and provides resilience when operating conditions or profitability fluctuate.
Balance SheetA sizable equity base and moderate leverage provide financial flexibility for a specialty biopharma company operating across rare-disease markets. This balance-sheet foundation can help Sobi sustain investment and absorb business volatility without relying excessively on additional borrowing.
Bears Say
Profitability DeclineThe sharp deterioration in net profitability weakens the predictability of Sobi’s earnings despite continued revenue growth and robust EBITDA margins. Thin net margins and much lower net income reduce retained funding capacity and increase the risk that reported results remain volatile over coming quarters.
Rising LeverageAlthough overall leverage remains moderate, the increase from 2025 narrows Sobi’s financial cushion relative to the prior year. Higher leverage can make future capital allocation less flexible and places greater importance on maintaining strong cash generation while profitability is under pressure.
Variable Cash ConversionCurrent cash generation is favorable, but uneven conversion across periods shows that reported operating performance does not consistently translate into cash. The prior negative free-cash-flow year highlights a structural need to monitor cash durability when funding growth and managing earnings volatility.
Swedish Orphan Biovitrum AB News
0MTD FAQ
What was Swedish Orphan Biovitrum AB’s price range in the past 12 months?
Swedish Orphan Biovitrum AB lowest share price was kr310.80 and its highest was kr486.40 in the past 12 months.
What is Swedish Orphan Biovitrum AB’s market cap?
Swedish Orphan Biovitrum AB’s market cap is kr156.74B.
When is Swedish Orphan Biovitrum AB’s upcoming earnings report date?
Swedish Orphan Biovitrum AB’s upcoming earnings report date is Oct 27, 2026 which is in 2 days.
How were Swedish Orphan Biovitrum AB’s earnings last quarter?
Swedish Orphan Biovitrum AB released its earnings results on Jul 16, 2026. The company reported kr3.14 earnings per share for the quarter, missing the consensus estimate of kr3.396 by -kr0.256.
Is Swedish Orphan Biovitrum AB overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum AB’s price is currently Undervalued.
Does Swedish Orphan Biovitrum AB pay dividends?
Swedish Orphan Biovitrum AB does not currently pay dividends.
What is Swedish Orphan Biovitrum AB’s EPS estimate?
Swedish Orphan Biovitrum AB’s EPS estimate is 6.02.
How many shares outstanding does Swedish Orphan Biovitrum AB have?
Swedish Orphan Biovitrum AB has 357,636,500 shares outstanding.
What happened to Swedish Orphan Biovitrum AB’s price movement after its last earnings report?
Swedish Orphan Biovitrum AB reported an EPS of kr3.14 in its last earnings report, missing expectations of kr3.396. Following the earnings report the stock price went up 2.058%.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum AB?
Currently, no hedge funds are holding shares in GB:0MTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
0MTD Stock 12 Month Forecast
Average Price Target
kr572.50
▲(24.26% Upside)
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
Orexo AB
―
Newbury Pharmaceuticals AB
―
Dicot Pharma AB
―